Ncardia Unveils Ncyte Heart in a Box for Cardiovascular Research

Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, announced the launch of Ncyte Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery.

“With Ncyte® Heart in a Box, we are empowering researchers to study complex cardiac biology with unprecedented precision, enabling breakthroughs in cardiovascular therapeutics and personalized medicine.”

Health Technology Insights: Nayya and Vensure Partner to Streamline Supplemental Health Claims

The Ncyte Heart in a Box system is derived from hiPSCs and integrates three essential cardiac cell types: ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts. Together, these high-purity components form a physiologically relevant microtissue that replicates the complexity and functionality of the human heart.

This innovative model offers a robust platform for studying heart development, disease progression, and cellular interactions within the cardiac environment. Researchers can leverage the enhanced predictive power of Ncyte Heart in a Box for therapeutic development, safety screening, and precision medicine applications.

Health Technology Insights: Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline

Key Benefits of Ncyte® Heart in a Box

Enhanced Physiological Relevance: Provides a multi-cellular cardiac model that mimics the native human heart microenvironment.
High-Purity iPSC-Derived Components: Incorporates ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts for more accurate disease modeling and drug testing.
Innovative 3D Microtissue Format: Supports more predictive, translationally relevant studies compared to traditional 2D cell cultures.

“This launch marks a significant milestone in cardiac research innovation,” said Jeroen de Groot, Divisional CEO of Ncardia. “With Ncyte Heart in a Box, we are empowering researchers to study complex cardiac biology with unprecedented precision, enabling breakthroughs in cardiovascular therapeutics and personalized medicine.”

Health Technology Insights: CommerceHealthcare Releases 2025 Healthcare Finance Trends Report

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – Businesswire

Tags: and TMEM119, IBA1, induced pluripotent stem cell, Ncardia, Ncyte Heart in a Box, TREM2

HealthTech Media Room

HealthTech Media Room is a leading B2B media publication platform providing in-depth coverage of the rapidly evolving healthcare technology and academic research sectors. Specializing in key focus areas such as MedTech, Pharma, Digital Health, Health IT, and Biotech, HealthTech Media Room delivers the latest news, trends, and insights across the entire HealthTech landscape. From breakthrough medical devices and innovative pharmaceuticals to cutting-edge digital health solutions, the platform highlights key players, strategic partnerships, and transformative technologies shaping the future of healthcare. Serving as a trusted resource for industry professionals, thought leaders, and healthcare organizations, HealthTech Media Room is dedicated to driving conversations and knowledge sharing in the global HealthTech community.